Search

Displaying results 3481 - 3490 of 7540 in total
  1. Drug

    Cytisine

    go.drugbank.com/drugs/DB09028
    Investigational

    Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost. … Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.

  2. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

    Synonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE
  3. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    It is being pursued by Access Pharmaceuticals, Inc. … AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  4. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875] … [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115].

  5. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone … Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  6. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  7. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases. rsPSMA Vaccine is a subunit vaccine based on

  8. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose[L30583]. … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].

  9. Drug

    Diatrizoate

    go.drugbank.com/drugs/DB00271
    ApprovedVet approved

    A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.

  10. Drug

    Troleandomycin

    go.drugbank.com/drugs/DB13179
    Approved

    A macrolide antibiotic that is similar to erythromycin.